Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsHypomethylating agents for adult patients with acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaAn update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesHistone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsTargeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeNew answers to old questions from genome-wide maps of DNA methylation in hematopoietic cellsHydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trialA comparison of azacitidine and decitabine activities in acute myeloid leukemia cell linesReassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposureHistone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid LeukemiaSequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.Decitabine: a review of its use in older patients with acute myeloid leukaemia.Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyEpigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancerGreen tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cellsLow-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II reportWhat are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.Epigenetic therapies in MDS and AMLA phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemiaA therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.Decitabine for acute myeloid leukemia.Targeting DNA methylation for epigenetic therapy.Leukaemogenesis: more than mutant genesEpigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.Clinical development of demethylating agents in hematologySmall-molecular modulators of cancer-associated epigenetic mechanisms.Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group reportImproving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience
P2860
Q21198868-CE1149C2-7173-43BF-B39E-C1CDA6117FE8Q24186284-FBBA0D31-02EB-477C-964B-3C1E29B9A636Q24234645-93EE01EF-2E34-4929-940B-53C1CA56E77AQ24622700-6D97A6CD-A18D-42A7-9587-16BD5857447EQ24633763-FF93A7DE-24C9-48A9-BACD-52404FEBC010Q26745731-C9BA9066-BE58-4588-83F8-94A6ACFC5372Q26770391-EEE8E688-E8E5-48D6-B826-1AB57BAF6B88Q26829132-BE87DBA8-93B9-4900-9165-FB3036BCA169Q26851510-10660B2C-C33C-49CF-9690-F3F6AF022A7DQ28294892-017187C0-B2F0-4385-8FD3-95BD05DB25E3Q28472733-8A43EDAC-1E42-49BE-A862-F50F0F9F80F4Q28534843-232919CB-11A1-4F66-B42E-098F7B4F0E19Q29394054-5466272E-C45E-441C-A1AF-71DE0369C9EEQ31149399-F351D56C-9A01-481C-A32C-354EF770FCF0Q33389485-944BD301-1491-4501-BAC2-96661E1B6D81Q33393266-748C24B1-DD0E-443A-A932-0F4156FA069EQ33396282-794B59B9-31C1-4CC3-B341-8E8478BD70D9Q33407030-FF66C874-2D1B-4332-BC24-9C7100B6E003Q33425338-22D5D519-BBC8-41BB-B597-FAF39749AE04Q33587441-B19D1C9E-4042-465C-9E06-EC31FDDDA6E1Q33595955-F386816D-5D5F-4263-85AE-0DD7CA3C76AEQ33744733-D0BA4826-E708-41D6-B252-34903CCBA2F3Q33775647-618E7391-063B-472C-8C1D-2C59A65DA564Q33841988-853DA225-FBD9-4351-A134-12C7BA431FB3Q33847891-9DF048FF-85BA-44EE-8863-D40296E6C956Q33863567-4EE99B4C-6654-4900-BDB1-DA46DE60E75AQ33939624-9EC3C4E3-E5AE-42EC-92BE-4DB5D1EC0A8EQ34014818-A00106FA-7103-4576-9FBB-595EFB8CAD33Q34052660-7B70358C-245B-45EA-B301-37B84863223FQ34084575-F3A73007-33EF-4347-A4F0-36AA6499A758Q34101643-3ACC4697-E6AE-421B-B207-30F928AE3A03Q34257184-D353CDCA-5585-4659-A89E-5D4D3687DD3CQ34258037-75565961-7CFB-4617-B080-1140A99397A0Q34275371-D31C608D-1C62-49B2-A50B-C27D38E00999Q34326174-FB3408EB-2B8E-4331-AC08-52667C14D7A7Q34395179-0D5094D6-443E-46D5-8011-32165BD13828Q34628002-B8C86B4B-D743-48D2-89BD-3A6A7086A436Q34676418-C42BA6BE-CE0D-4842-BEC1-C23A3F2057D6Q34722045-47E7CA39-E52A-4B92-915B-A88965D2D385Q34772229-71AD5DC9-BBFC-4516-A4AC-3929E9E02F01
P2860
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@ast
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@en
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@nl
type
label
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@ast
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@en
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@nl
prefLabel
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@ast
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@en
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@nl
P2093
P50
P356
P1476
Phase I study of decitabine al ...... cid in acute myeloid leukemia.
@en
P2093
Anthony Murgo
Bjoern Hackanson
Cheryl Kefauver
Christoph Plass
Gerard Lozanski
Hollie Devine
Kenneth K Chan
Lenguyen Huynh
Michael R Grever
Rebecca B Klisovic
P304
P356
10.1200/JCO.2006.09.4169
P407
P577
2007-08-06T00:00:00Z